TC
AVXL icon

TwinBeech Capital’s Anavex Life Sciences AVXL Stock Holding History

TwinBeech Capital’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,944
Closed -$231K – 596
2025
Q3 		$231K Buy
+25,944
New +$263K 0.01% 506
2022
Q2 		– Sell
-47,909
Closed -$590K – 499
2022
Q1 		$590K Buy
+47,909
New +$589K 0.03% 381

Other funds holding AVXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TwinBeech Capital's AVXL Position: Q4 2025 in Review

TwinBeech Capital sold out of Anavex Life Sciences (AVXL) in Q4 2025, closing a stake of 25,944 shares — an estimated $231K sold.

TwinBeech Capital first reported a position in AVXL in Q1 2022 and held it in 2 quarters. The position peaked at $590K in Q1 2022. 183 funds tracked by Wall St. Rank hold AVXL as of Q4 2025.

  • TwinBeech Capital reported no remaining Anavex Life Sciences position as of Q4 2025 after selling out during the quarter.
  • TwinBeech Capital sold 25,944 Anavex Life Sciences shares in Q4 2025, an estimated $231K.
  • TwinBeech Capital first reported a position in Anavex Life Sciences in Q1 2022 and held it in 2 quarters.
  • TwinBeech Capital's Anavex Life Sciences position peaked at $590K in Q1 2022.
  • 183 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2025.

Based on TwinBeech Capital's 13F filing for Q4 2025, filed 17 Feb 2026.